Prakt. lékáren. 2016; 12(4): 150-153 | DOI: 10.36290/lek.2016.036

Multidisciplinary team approach of paediatrician, neurologist and a clinical pharmacist in management of a paediatric

Petra Thomson1,2, Pavel Rozsíval3,4
1 Nemocniční lékárna, Fakultní nemocnice Hradec Králové
2 Farmaceutická fakulta v Hradci Králové, Univerzita Karlova v Praze
3 Dětská klinika, Fakultní nemocnice Hradec Králové
4 Lékařská fakulta v Hradci Králové, Univerzita Karlova v Praze

patient with pharmacoresistant epilepsy

Young patient suffering from pharmacoresistant epilepsy poses a complicated case due to medication interactions, correct dose

calculation, suitable drug formulation and need for off-label therapy or extemporaneous preparation, as shown in the presented

patient case.

Keywords: pharmacoresistant epilepsy, clinical pharmacy, drug interactions, intoxication, drug formulation, extemporaneous

Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Thomson P, Rozsíval P. Multidisciplinary team approach of paediatrician, neurologist and a clinical pharmacist in management of a paediatric. Praktické lékárenství. 2016;12(4):150-153. doi: 10.36290/lek.2016.036.
Download citation

References

  1. Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol. 2011; 53 Suppl 2: 16-18. doi: 10.1111/j.1469-8749.2011.03967.x Go to original source... Go to PubMed...
  2. Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet Syndrome. Paediatr Drugs. 2016 Mar 10, publikováno online před tiskem. Go to original source... Go to PubMed...
  3. Souhrn údajů o přípravku Diacomit 250 mg POR PLV SUS, zdroj: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf, citováno 18/04/2016.
  4. Inoue Y, Ohtsuka Y, Ikeda S, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia (Series 4), November 2009; 50(11): 2362-2368, citováno 18/04/2016. Go to original source... Go to PubMed...
  5. Mewasingh LD, Sékhara T, Aeby A, Christiaens FJ, Dan B. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003; 12(7): 483-489. Go to original source... Go to PubMed...
  6. Sztajnkrycer MD. Valproic acid toxicity: overview and management. Journal Of Toxicology. Clinical Toxicology. 2002; 40(6): 789-801. Go to original source... Go to PubMed...
  7. British National Formulary for Children, Valproic acid monografie, naposledy aktualizováno 23. března 2016, citováno 17/04/2016.
  8. Sodium valproate for preventing seizures leaflet, Medicines for Children UK, http://www.medicinesforchildren.org.uk/sodium-valproate-preventing-seizures, poslední revize textu 07/03/2014, citováno 17/04/2016.
  9. Souhrn údajů o přípravku Ebixa 10 mg POR TBL FLM, zdroj: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000463/WC500058763.pdf, citováno 18/04/2016.
  10. Hani AJ, Mikati HM, Mikati MA. Genetics of pediatric epilepsy. Pediatr Clin North Am. 2015; 62(3): 703-722. Go to original source... Go to PubMed...
  11. Pierson TM, Yuan H, Marsh ED, et al. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Annals of Clinical and Translational Neurology. 2014; 1(3): 190-198. doi:10.1002/acn3. 39. Go to original source... Go to PubMed...
  12. Czaja AS, Reiter PD, Schultz ML, Valuck RJ. Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research. J Pediatr Pharmacol Ther. 2015; 20(3): 186-196. Go to original source... Go to PubMed...
  13. White R, Brandam V. Handbook of Drug Administration via Enteral Feeding Tubes, monografie Sodium valproate, přes www. medicinescomplete.com, citováno 18/04/2016.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.